ClinicalTrials.gg

Program

GSK4771261

A development code.

In GlaxoSmithKline's pipeline, Monoclonal antibody against novel kidney target. Its studies are mostly in Kidney Diseases · Polycystic Kidney, Autosomal Dominant, led by GlaxoSmithKline.

Furthest: phase 1, since Dec 11, 20242 company-led studies, 2 open or runningNext primary completion: May 20, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline22 open or runningphase 1since Dec 11, 2024Dec 11, 2024May 20, 2027phase 1 · NCT07600450
  • Named in GlaxoSmithKline’s own pipeline as GSK4771261, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 11, 2024First study: phase 1 study in Kidney DiseasesFirst studyNCT06734234 · 86 enrolled · United States, Belgium, Canada and more
  2. May 14, 2026Phase 1 study in Kidney DiseasesNCT07600450 · 30 planned · Netherlands
  3. Oct 5, 2026Primary completion moved from 2026-09-22 to 2027-05-20Date moved laterphase 1 · +8 months · NCT07600450

Ahead

  1. May 20, 2027Primary completion: phase 1 study in Kidney DiseasesNCT07600450
  2. Jul 23, 2027Primary completion: phase 1 study in Kidney DiseasesNCT06734234

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Monoclonal antibody against novel kidney target”the company's pipeline, read by Claude · source

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07600450Kidney Diseases · Netherlands1RecruitingMay 20, 202730
NCT06734234Kidney Diseases · United States, Belgium, Canada and more1Active, not recruitingJul 23, 202786

How it is read

Names in the registry

  • “GSK4771261”, 2 entries

Codes read as this program: GSK4771261.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.